{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:53:28Z","timestamp":1766141608903,"version":"3.48.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"DOI":"10.7759\/cureus.99602","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:48:35Z","timestamp":1766141315000},"source":"Crossref","is-referenced-by-count":0,"title":["Denosumab Versus Bisphosphonates in Glucocorticoid-Induced Osteoporosis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Anas E","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed A","family":"Alzaylaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah S","family":"Suhluli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahd A","family":"Essa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latifah M","family":"Bahkali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanood M","family":"Hakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razan A","family":"Alshamrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad R","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roaa H","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tassnim H","family":"Khurayzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulmalik K","family":"Almihbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4551","article-title":"Effect of denosumab compared with risedronate on bone strength in patients initiating or continuing glucocorticoid treatment","volume":"37","author":"Geusens P","year":"2022","unstructured":"Geusens P, Bevers MS, van Rietbergen B, et al.. Effect of denosumab compared with risedronate on bone strength in patients initiating or continuing glucocorticoid treatment. J Bone Miner Res. 2022, 37:1136-46. 10.1002\/jbmr.4551","journal-title":"J Bone Miner Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115902","article-title":"Denosumab versus alendronate in long-term glucocorticoid users: a 12-month randomized controlled trial","volume":"146","author":"Mok CC","year":"2021","unstructured":"Mok CC, Ho LY, Leung SM, Cheung HN, Chen SP, Ma KM. Denosumab versus alendronate in long-term glucocorticoid users: a 12-month randomized controlled trial. Bone. 2021, 146:115902. 10.1016\/j.bone.2021.115902","journal-title":"Bone"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag KG","year":"2019","unstructured":"Saag KG, Pannacciulli N, Geusens P, et al.. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol. 2019, 71:1174-84. 10.1002\/art.40874","journal-title":"Arthritis Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3954-24","article-title":"Effects of denosumab and bisphosphonates on glucocorticoid-induced osteoporosis in patients with neuroimmunological disorders","volume":"64","author":"Handa H","year":"2025","unstructured":"Handa H, Uzawa A, Mori M, et al.. Effects of denosumab and bisphosphonates on glucocorticoid-induced osteoporosis in patients with neuroimmunological disorders. Intern Med. 2025, 64:543-9. 10.2169\/internalmedicine.3954-24","journal-title":"Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.03.002","article-title":"Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial","volume":"75","author":"Mok CC","year":"2015","unstructured":"Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone. 2015, 75:222-8. 10.1016\/j.bone.2015.03.002","journal-title":"Bone"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193846","article-title":"The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial","volume":"13","author":"Iseri K","year":"2018","unstructured":"Iseri K, Iyoda M, Watanabe M, et al.. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial. PLoS One. 2018, 13:e0193846. 10.1371\/journal.pone.0193846","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt C","year":"2007","unstructured":"Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007, 7:16. 10.1186\/1472-6947-7-16","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs SH","year":"1998","unstructured":"Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998, 52:377-84. 10.1136\/jech.52.6.377","journal-title":"J Epidemiol Community Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/447756-denosumab-versus-bisphosphonates-in-glucocorticoid-induced-osteoporosis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:48:36Z","timestamp":1766141316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/447756-denosumab-versus-bisphosphonates-in-glucocorticoid-induced-osteoporosis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.99602","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}